Weiter zum Inhalt
Toggle navigation
English
English
Favoritenliste (
0
)
(Voll)
Kontakt
Mein Konto
Abmeldung
Mein Konto
Suche
Filter bei nächster Suche beibehalten
topic_facet:"Phase: Phase 1/Phase 2"
topic_facet:"Recruitment Status: Withdrawn"
Erweiterte Suche
Suchverlauf
Struktursuche
Narrative Service
Drug Overviews
Info Guide
/vufind/Search/Results?filter%5B%5D=topic_facet%3A%22Phase%3A+Phase+1%2FPhase+2%22&filter%5B%5D=topic_facet%3A%22Recruitment+Status%3A+Withdrawn%22&lookfor=%22Study+Type%3A+Interventional%22&type=Subject
/vufind/Search/Results?filter%5B%5D=topic_facet%3A%22Phase%3A+Phase+1%2FPhase+2%22&filter%5B%5D=topic_facet%3A%22Recruitment+Status%3A+Withdrawn%22&lookfor=%22Study+Type%3A+Interventional%22&type=Subject
Search /vufind/Search2/Results?filter%5B%5D=topic_facet%3A%22Phase%3A+Phase+1%2FPhase+2%22&filter%5B%5D=topic_facet%3A%22Recruitment+Status%3A+Withdrawn%22&lookfor=%22Study+Type%3A+Interventional%22&type=Subject
PubPharm (454)
1
Study to evaluate the safety, tolerability and efficacy parameters of the drug PRX-102 administered by intravenous infusion every 2 weeks for 12 weeks, to adult patients with Fabry disease : A Phase 1/2, Open Label, Dose Ranging Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Exploratory Efficacy Parameters of PRX-102 Administered by Intravenous Infusion Every 2 Weeks for 12 Weeks to Adult Fabry Patients
enthalten in:
WHO International Clinical Trials Registry Platform
| 2023
Wird geladen...
2
Study to evaluate the safety, tolerability and efficacy parameters of the drug PRX-102 administered by intravenous infusion every 2 weeks for 12 weeks, to adult patients with Fabry disease : A Phase 1/2, Open Label, Dose Ranging Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Exploratory Efficacy Parameters of PRX-102 Administered by Intravenous Infusion Every 2 Weeks for 12 Weeks to Adult Fabry Patients
enthalten in:
WHO International Clinical Trials Registry Platform
| 2023
Wird geladen...
3
Tocilizumab for tReatment Of COVID-19 in intensive cARe patients (TROCAR”) : Tocilizumab for the treatment of COVID-19 in intensive care patients: effect on days free of ventilatory support.
enthalten in:
WHO International Clinical Trials Registry Platform
| 2022
Wird geladen...
4
Tocilizumab for tReatment Of COVID-19 in intensive cARe patients (TROCAR”) : Tocilizumab for the treatment of COVID-19 in intensive care patients: effect on days free of ventilatory support.
enthalten in:
WHO International Clinical Trials Registry Platform
| 2022
Wird geladen...
5
A phase II open label study to determine the ocular pharmacokinetics of oral OCX063. : A phase II open label study to determine the ocular pharmacokinetics of oral OCX063, in patients requiring retinal reattachment surgery.
enthalten in:
WHO International Clinical Trials Registry Platform
| 2022
Wird geladen...
6
A phase II open label study to determine the ocular pharmacokinetics of oral OCX063. : A phase II open label study to determine the ocular pharmacokinetics of oral OCX063, in patients requiring retinal reattachment surgery.
enthalten in:
WHO International Clinical Trials Registry Platform
| 2022
Wird geladen...
7
Breast Cancer Vaccine in Combination With Pembrolizumab for Treatment of Persistent, Recurrent, or Metastatic Breast Cancer : A Phase I/II Study of the SV-BR-1-GM Regimen in HLA Matched Metastatic Breast Cancer Patients in Combination With Pembrolizumab
enthalten in:
ClinicalTrials.gov
| 2021
Wird geladen...
8
CD24Fc With Ipilimumab and Nivolumab to Decrease irAE (CINDI) : Phase Ib/II Study Combining CD24Fc With Checkpoint Inhibitors for Patients With Metastatic Melanoma
enthalten in:
ClinicalTrials.gov
| 2021
Wird geladen...
9
Effects of mTOR Inhibition With Sirolimus (RAPA) in Patients With COVID-19 to Moderate the Progression of ARDS : Effects of mTOR Inhibition With Sirolimus (RAPA) in Patients With COVID-19 to Moderate the Progression of Acute Respiratory Distress Syndrome (RAPA-CARDS)
enthalten in:
ClinicalTrials.gov
| 2021
Wird geladen...
10
Optimising Anterior Pallidal Deep Brain Stimulation for Tourette's Syndrome : Optimising Anterior Pallidal Deep Brain Stimulation for Tourette's Syndrome - A Pilot Study
enthalten in:
ClinicalTrials.gov
| 2021
Wird geladen...
1
2
3
4
5
6
7
8
9
10
11
Nächster »
[46]
Filter & Sortierung
Treffer pro Seite
10
20
50
Sortieren
Relevanz
Neueste zuerst
Älteste zuerst
Verfasser
Zeitschriftentitel
Bibliothek
Standort (Printmedien)
Verwandte Substanzen
Verwandte Substanzen werden ermittelt...
Verwandte Erkrankungen/Symptome
Verwandte Erkrankungen/Symptome werden ermittelt...
Verwandte Gene
Verwandte Gene werden ermittelt...
Systematic Reviews
Clinical Studies
Patente
Covid-19/SARS-CoV-2
Exclude Systematic Reviews
Exclude Clinical Studies
Exclude Patents
Ihre gewählten Filter
Filter bei nächster Suche beibehalten
Filter aufheben
Alle gewählten Filter entfernen
Filter aufheben
Thema: Phase: Phase 1/Phase 2
Filter aufheben
Thema: Recruitment Status: Withdrawn
Medienart
454
Aufsätze
454
E-Artikel
454
E-Ressourcen
Zeitschriftentitel
424
ClinicalTrials.gov
30
WHO International Clinical Trials Registry Plat...
Thema
454
610
Phase: Phase 1/Phase 2
Recruitment Status: Withdrawn
454
Study Type: Interventional
28
Lymphoma
23
Leukemia
22
Carcinoma
20
Lung Neoplasms
20
Syndrome
19
Breast Neoplasms
19
Melanoma
13
Leukemia, Myeloid
11
Adenocarcinoma
11
Carcinoma, Non-Small-Cell Lung
11
Leukemia, Myeloid, Acute
10
Lymphoma, Non-Hodgkin
10
Myelodysplastic Syndromes
10
Neoplasms
10
Pancreatic Neoplasms
10
Preleukemia
Alle anzeigen ...
weniger ...
Erscheinungszeitraum
125
2020-
321
2010-2019
8
2000-2009
Erscheinungsjahr(e)
Von:
Bis:
Sprache
452
Englisch
2
Unbestimmt
Haven't found what you're looking for?
Wird geladen...